Sacrosidase

Treats sucrase deficiency. Sold as Sucraid. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Sacrosidase (sold as Sucraid), first approved Apr 9, 1998, with 0 new uses approved and 0 published complete response letters.

First approved: Apr 9, 1998
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $129M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Sucraid	Part D	$129M	+20%	2,414

Orphan Designations (FDA)

One designation, 1 approved for the designated use; see all orphan designations

Treatment of congenital sucrase-isomaltase deficiencyQOL Medical, LLC · designated Dec 10, 1993 · approved Apr 9, 1998

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Apr 9, 1998	SucraidBLA 20772 · New molecular entity	Qol Medcl	15	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA